-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Original title: Kang Cai | Annual report net profit: Zhongsheng United lost 58 million yuan Yiling Pharmaceutical 1.
Zhongsheng United's loss in 2020 narrows
Zhongsheng United's loss in 2020 narrows Zhongsheng United's loss in 2020 narrowsZhongsheng United (03332) issued an announcement that the group's revenue as of 2020 is expected to decrease by about 8% compared with that of 2019.
Zhongsheng United (03332) issued an announcement that the group's revenue as of 2020 is expected to decrease by about 8% compared with that of 2019.
The company stated that in 2020, the COVID -19 epidemic will have a greater impact on the sales revenue of Living Nature Natural Products Limited.
Yisheng Pharmaceutical's 2020 net profit is about 79.
On February 25, Yisheng Pharmaceutical released the 2020 annual results bulletin.
Mainly due to the impact of the new crown pneumonia epidemic during the reporting period, the company's main market terminal hospitals and franchised beauty salons and other offline channels were affected to a certain extent, resulting in a decrease in the company's operating income from the same period last year.
Yiling Pharmaceutical: 2020 net profit of approximately 1.
On February 25, Yiling Pharmaceutical released the 2020 annual results bulletin.
The increase in the company’s total operating income in 2020 is mainly due to the significant increase in the brand awareness of the company’s Lianhua Qingwen products during the reporting period, a significant increase in domestic market demand, and sales in more than ten registered overseas countries.
Blue Crystal Microbes completed nearly 200 million yuan in Series B financing
On February 26, Bluepha announced the completion of a Series B financing of nearly RMB 200 million.
On February 26, Bluepha announced the completion of a Series B financing of nearly RMB 200 million.
Established in 2016, Kyanite Microbe is a start-up company engaged in molecular and material innovation based on synthetic biotechnology.
Livzon Biotech obtains the new "Business License".
Livzon Biotech’s shareholders are changed to the company, Joincare, YF Pharmab Limited (YF) and Hainan Lisheng Juyuan Investment Partnership (Limited Partnership), and Livzon Bio’s registered capital is increased to RMB 889 million.
